Theracryf Plc (LON:TCF)
0.21p-8.51%
Spriggl Score: Moderate— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Clinical progress masks severe dilution history; cash runway expires end-2026 with no guaranteed funding in sight.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Theracryf Plc
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibi…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £5.1M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Theracryf Plc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free